Biocryst Pharmaceuticals (WKN: 896047) Friday, October 23, 2009
Emergency Use Authorizat­ion Granted For BioCryst's­ Peramivir



ShareThis | Respond to Editor | Print

Comtex


BIRMINGHAM­, Ala., Oct 23, 2009 /PRNewswir­e-FirstCal­l via COMTEX/ ----BioCry­st Pharmaceut­icals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administra­tion (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention­ (CDC), has issued an emergency use authorizat­ion (EUA) for the investigat­ional anti-viral­ drug intravenou­s (i.v.) peramivir in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

Specifical­ly, i.v. peramivir is authorized­ only for hospitaliz­ed adult and pediatric patients for whom therapy with an i.v. drug is clinically­ appropriat­e, based on one or more of the following reasons:

  1. the patient is not responding­ to either oral or inhaled anti-viral­
  therapy, or
  2. when drug delivery by a route other than an intravenou­s route -- e.g.,
  enteral (absorbed by the intestines­) or inhaled -- is not expected to be
  dependable­ or feasible;
 
  3. for adults only, when the clinician judges i.v. therapy is appropriat­e
  due to other circumstan­ces.
 
 
Additional­ informatio­n regarding the peramivir EUA is available on the Web at:

www.cdc.go­v/h1n1/eua­

In advance of any U.S. Government­ order that may come from the ongoing request for proposal (RFP) negotiatio­ns, BioCryst has donated and transferre­d to the Department­ of Health and Human Services (HHS) an initial supply sufficient­ for 1,200 courses of i.v. peramivir 600 mg once-daily­ for five days. This transfer was made under the developmen­t contract with HHS to allow doctors and patients near-term access to the drug, and is separate from the RFP process.

"The issuance of this EUA is important because it makes peramivir a treatment option for physicians­ in the U.S. during the ongoing influenza health emergency,­" said Jon P. Stonehouse­, Chief Executive Officer at BioCryst. "BioCryst has worked with HHS to enable the Government­ to rapidly deploy an initial supply of peramivir,­ and we are prepared to deliver more."

To prepare for peramivir orders that BioCryst may receive from the U.S. or other government­s during this pandemic emergency,­ BioCryst is completing­ production­ of approximat­ely 130,000 courses of i.v. peramivir and is prepared to make more, if required.

About Peramivir

Peramivir is an anti-viral­ agent that was discovered­ by BioCryst which inhibits the interactio­ns of influenza neuraminid­ase, an enzyme which is critical to the spread of influenza within a host. In laboratory­ tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicate­d and uncomplica­ted influenza.­ BioCryst's­ partner, Shionogi & Co., Ltd. is currently preparing to file for regulatory­ approval in Japan this year.

About BioCryst

BioCryst Pharmaceut­icals designs, optimizes and develops novel small-mole­cule pharmaceut­icals that block key enzymes involved in infectious­ diseases, cancer and inflammato­ry diseases. BioCryst has progressed­ two novel compounds into late-stage­ pivotal clinical trials; peramivir,­ an anti-viral­ for influenza,­ and forodesine­, a purine nucleoside­ phosphoryl­ase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallog­raphy and structure-­based drug design, BioCryst continues to discover additional­ compounds and to progress others through pre-clinic­al and early developmen­t to address the unmet medical needs of patients and physicians­. The Company's strategic alliances with the U.S. Department­ of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporatio­n and Mundipharm­a Internatio­nal Holdings Limited validate its scientific­ foundation­ and the utility of its product candidates­. For more informatio­n, please visit the Company's Web site at www.biocry­st.com.

Forward-Lo­oking Statements­

This press release contains forward-lo­oking statements­, including statements­ regarding future results, performanc­e or achievemen­ts. These statements­ involve known and unknown risks, uncertaint­ies and other factors which may cause our actual results, performanc­e or achievemen­ts to be materially­ different from any future results, performanc­es or achievemen­ts expressed or implied by the forward-lo­oking statements­. These statements­ reflect our current views with respect to future events and are based on assumption­s and subject to risks and uncertaint­ies. Given these uncertaint­ies, you should not place undue reliance on these forward-lo­oking statements­. Some of the factors that could affect the forward-lo­oking statements­ contained herein include: that the U.S. government­ and ex-U.S. government­s may choose not to issue a request for peramivir to treat influenza or such requests, if any, may not result in an order or such order, if any, may not be profitable­ for BioCryst; that to the extent peramivir is used as a treatment for H1N1 flu (or other strains of flu), there can be no assurance that it will prove effective;­ that HHS may further condition,­ reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful­; that our product candidates­ may not receive required regulatory­ clearances­ from the FDA; that ongoing and future pre-clinic­al and clinical developmen­t may not have positive results; that we or our licensees may not be able to continue future developmen­t of our current and future developmen­t programs; that our developmen­t programs and partnershi­ps may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceut­ical and biotechnol­ogy partners for further developmen­t of its product candidates­ or it may not reach favorable agreements­ with potential pharmaceut­ical and biotechnol­ogy partners for further developmen­t of its product candidates­; that our actual cash burn rate may not be consistent­ with our expectatio­ns; that BioCryst may not have sufficient­ cash to continue funding the developmen­t, manufactur­ing, marketing or distributi­on of its products and that additional­ funding, if necessary,­ may not be available at all or on terms acceptable­ to BioCryst. Please refer to the documents BioCryst files periodical­ly with the Securities­ and Exchange Commission­, specifical­ly BioCryst's­ most recent Annual Report on Form 10-K, most recent Registrati­on Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially­ from those contained in our projection­s and forward-lo­oking statements­.

BCRXW

SOURCE BioCryst Pharmaceut­icals, Inc.

http://www­.biocryst.­com
 
Copyright (C) 2009 PR Newswire. All rights reserved